A multicenter clinical trial in the Arab world

被引:1
作者
Abbas, EE
Dham, P
Shaker, D
机构
[1] Saif Bin Gobash Hosp, Ras Alkhaima, U Arab Emirates
[2] Ibrahim Bin Harnad Obaidullah Hosp, Ras Alkhaima, U Arab Emirates
[3] Julphar Drug Informat Dept, Dubai, U Arab Emirates
关键词
D O I
10.1016/j.transproceed.2004.07.037
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Financial, social, and perhaps religious, ethical, and other factors hinder investment and performance of clinical research in Arab countries. We report in that conducting multicenter clinical trials is feasible in the Arab world, describing our experience in planning and conducting one of the first multicenter, multinational, clinical trials in the region. A multicenter clinical trial sought to document the efficacy and safety of Epotin for the treatment of anemia in patients on maintenance hemodialysis. Among 29 centers contacted for participation, a positive response was obtained from 17 (62%) located in eight countries. The initial recruitment period of 3 months was extended to 1 year. Among the participating centers, 16 forwarded their results in time, with one being late. There were minor and a few major protocol violations, the latter requiring exclusion of data from the final analysis. Sponsorship was mainly by a local pharmaceutical company (Julphar). A co-coordinating body was crucial to trace and gather the data. Since conduct of the trial required considerable time and effort from investigators, the use of modern information technology could have reduced the effort and improved the outcomes. We conclude that multicenter clinical trials, which are essential can be conducted in this region. This experience needs to be repeated and refined.
引用
收藏
页码:1801 / 1804
页数:4
相关论文
共 19 条
[1]  
Al-Khader AA, 2002, SAUDI MED J, V23, P1177
[2]  
Badrane Hassan, 2003, Tunis Med, V81, P377
[3]   Data and safety monitoring board issues raised in the VA Status Epilepticus Study [J].
Collins, JF .
CONTROLLED CLINICAL TRIALS, 2003, 24 (01) :71-77
[4]   Sponsorship, authorship, and accountability. [J].
Davidoff, F ;
DeAngelis, CD ;
Drazen, JM ;
Hoey, J ;
Hojgaard, L ;
Horton, R ;
Kotzin, S ;
Nicholls, MG ;
Nylenna, M ;
Overbeke, AJPM ;
Sox, HC ;
Van Der Weyden, MB ;
Wilkes, MS .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (11) :825-827
[5]  
Hauke C, 2001, Injury, V32 Suppl 2, pB26
[6]   Health supercourse to end Arab isolation [J].
Husseini, A ;
Saad, R ;
LaPorte, RE .
NATURE, 2002, 417 (6891) :788-788
[7]  
KAO LS, 2003, ARCH SURG-CHICAGO, P138
[8]   Ethics of clinical research in the developing world [J].
Killen, J ;
Grady, C ;
Folkers, GK ;
Fauci, AS .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (03) :210-215
[9]   Who is my brother's keeper? [J].
Kottow, MH .
JOURNAL OF MEDICAL ETHICS, 2002, 28 (01) :24-27
[10]   Anemia and end-stage renal disease in the developing world [J].
Maïz, HB ;
Abderrahim, E ;
Zouaghi, K .
ARTIFICIAL ORGANS, 2002, 26 (09) :760-764